The current price-to-earnings ratio of ZYME can't be determined, as the TTM EPS of -$1.49 is negative. The most recent PE ratio recorded for Zymeworks was 1.96 in September 2023.
Over the last seven years, the average PE ratio of Zymeworks has been 65.27. In the past seven years, ZYME's PE ratio reached its highest point in the Sep 2018 quarter at 314, with a price of $15.7 and an EPS of $0.05. The Sep 2023 quarter saw the lowest point at 1.96, with a price of $6.34 and an EPS of $3.24.
Year | PE ratio | Change |
---|---|---|
2023 | N/A | N/A |
2022 | 4.12 | N/A |
2021 | N/A | N/A |
2020 | N/A | N/A |
2019 | N/A | N/A |
2018 | N/A | N/A |
2017 | N/A | N/A |
2016 | N/A | N/A |
2015 | N/A | N/A |
2014 | N/A | N/A |
Stock name | PE ratio | Market cap |
---|---|---|
ORMP Oramed Pharmaceuticals Inc | 21 | $93.12M |
OLMA Olema Pharmaceuticals Inc | N/A | $450.93M |
OMER Omeros Corp | N/A | $447.95M |
OMGA Omega Therapeutics Inc | N/A | $42.96M |
ONCT Oncternal Therapeutics Inc | N/A | $3.43M |
ONVO Organovo Holdings Inc | N/A | $5.38M |
ORIC Oric Pharmaceuticals Inc | N/A | $643.57M |
ZYME Zymeworks Inc | N/A | $942.24M |
The current price to earnings ratio of ZYME can't be calculated, as its EPS of -$1.49 is negative.
Over the last seven years, the quarterly PE ratio reached a historic high of 314 in the Sep 2018 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.